Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ProQR Therapeutics N.V.
  6. Summary
    PRQR   NL0010872495

PROQR THERAPEUTICS N.V.

(PRQR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
0.6741(c) 0.688(c) 0.6444(c) 0.6264(c) 0.638(c) Last
236 691 638 267 436 027 493 986 250 983 Volume
+4.97% +2.06% -6.34% -2.79% +1.85% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4,14 M - -
Net income 2022 -67,1 M - -
Net cash position 2022 80,8 M - -
P/E ratio 2022 -0,73x
Yield 2022 -
Sales 2023 5,21 M - -
Net income 2023 -57,9 M - -
Net cash position 2023 17,3 M - -
P/E ratio 2023 -0,81x
Yield 2023 -
Capitalization 45,5 M 45,5 M -
EV / Sales 2022 -8,52x
EV / Sales 2023 5,43x
Nbr of Employees -
Free-Float 87,8%
More Financials
Company
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic... 
Read more
More about the company
Ratings of ProQR Therapeutics N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROQR THERAPEUTICS N.V.
05/10ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide ..
AQ
05/09HC Wainwright Lowers ProQR Therapeutics N.V's Price Target to $2 From $4, Buy Rating Ke..
MT
05/09ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide..
GL
05/09ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide..
GL
05/06Chardan Lowers Price Target for ProQR Therapeutics N.V to $2 From $2.50, Maintains Buy ..
MT
05/05PROQR : Q1 Earnings Snapshot
AQ
05/05ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/05ProQR Announces First Quarter 2022 Operating and Financial Results
GL
04/26ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Associa..
GL
04/26ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Associa..
GL
04/20ProQR Therapeutics to Participate in the Kempen Life Sciences Conference
AQ
04/19ProQR to Participate in the Kempen Life Sciences Conference
GL
04/19ProQR to Participate in the Kempen Life Sciences Conference
GL
04/14Chardan Capital Adjusts Price Target for ProQR Therapeutics N.V to $2.50 From $8, Maint..
MT
04/14JMP Securities Adjusts ProQR Therapeutics' Price Target to $5 from $8, Keeps Market Out..
MT
More news
News in other languages on PROQR THERAPEUTICS N.V.
05/05ProQR Therapeutics N.V. annonce ses résultats pour le premier trimestre clos le 31 mars..
04/13ProQR Therapeutics N.V. annonce des analyses supplémentaires de l'essai Sepofarsen Illu..
03/08La Foundation Fighting Blindness et InformedDNA s'associent pour engager et dépister le..
03/07ProQR Therapeutics N.V. nomme John Maraganore au poste de conseiller stratégique du con..
02/24ProQR Therapeutics N.V. annonce ses résultats pour l'année complète se terminant le 31 ..
More news
Analyst Recommendations on PROQR THERAPEUTICS N.V.
More recommendations
Chart PROQR THERAPEUTICS N.V.
Duration : Period :
ProQR Therapeutics N.V. Technical Analysis Chart | PRQR | NL0010872495 | MarketScreener
Technical analysis trends PROQR THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 0,64 $
Average target price 2,42 $
Spread / Average Target 279%
EPS Revisions
Managers and Directors
Daniel Anton de Boer Chief Executive Officer
Smital Shah Chief Financial & Business Officer
Domenico Valerio Chairman-Supervisory Board
Aniz Girach Chief Medical Officer
Jennifer Pluim Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
PROQR THERAPEUTICS N.V.-92.04%46
GILEAD SCIENCES, INC.-11.21%80 866
REGENERON PHARMACEUTICALS, INC.8.22%73 638
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-25.70%37 870